A differential response to newt regeneration extract by C2C12 and primary mammalian muscle cells by Sarah Kawesa et al.
Kawesa et al. Skeletal Muscle  (2015) 5:19 
DOI 10.1186/s13395-015-0044-8RESEARCH Open AccessA differential response to newt
regeneration extract by C2C12 and primary
mammalian muscle cells
Sarah Kawesa1,2, Jason Vanstone1,2,3 and Catherine Tsilfidis1,2*Abstract
Background: Dedifferentiation, a process whereby differentiated cells lose their specialized characteristics and revert
to a less differentiated state, plays a key role in the regeneration process in urodele amphibians such as the red spotted
newt, Notophthalmus viridescens. Dedifferentiation of fully mature tissues is generally absent in mammalian cells.
Previous studies have shown that mouse C2C12 multinucleated myotubes treated with extract derived from
regenerating newt forelimbs can re-enter the cell cycle, fragment into mononucleated cells, and proliferate. However,
this response has been difficult to replicate.
Methods: We isolated extract from early newt forelimb regenerates and assessed its effects on differentiation of
proliferating primary and C2C12 myoblasts. We also treated fully differentiated primary and C2C12 myotube cultures
with extract and assessed cell cycle re-entry and myotube fragmentation.
Results: We have confirmed the results obtained in C2C12 cells and expanded these studies to also examine the
effects of newt regeneration extracts on primary muscle cells. Newt extract can block differentiation of both
C2C12 and primary myoblasts. Once differentiation is induced, treatment with newt extract causes cell cycle re-
entry and fragmentation of C2C12 myotubes. Downregulation of p21 and muscle-specific markers is also induced.
Primary myotubes also fragment in response to extract treatment, and the fragmented cells remain viable for
long periods of time in culture. However, unlike C2C12 cells, primary muscle cells do not re-enter the cell cycle in
response to treatment with newt extracts.
Conclusions: Dedifferentiation of fully mature muscle occurs during regeneration in the newt forelimb to
contribute cells to the regeneration process. Our study shows that extracts derived from regenerating newt
forelimbs can induce dedifferentiation, cell cycle re-entry, and fragmentation of mouse C2C12 cells but can only
induce fragmentation in primary muscle cells.
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Tissue regeneration is a complex process of replacing
cells lost due to disease or injury [1, 2]. All eukaryotes
have basic regenerative abilities such as wound closure
and tissue repair. The most complex form of regener-
ation is known as epimorphic regeneration. This is mas-
tered by the urodele amphibians (newts and axolotls).* Correspondence: ctsilfidis@ohri.ca
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creativecommons.org/publicdomain/zero/1.0/Epimorphic limb regeneration involves four major phases:
wound healing, dedifferentiation, blastema formation, and
redifferentiation [3]. It is believed that the dedifferenti-
ation process is the key to regeneration [4, 5]. Through
this process, differentiated cells re-enter the cell cycle and
revert back to a progenitor phenotype [6–8] that can then
proliferate and re-differentiate into the various tissues of
the regenerated structure.
In mammals, dedifferentiation of fully differentiated
muscle does not occur during the regeneration process.
Satellite cells are the source of cells for regeneration
of damaged mammalian muscle (see review [9]).rticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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also the source of cells for muscle regeneration in the
axolotl, a urodele amphibian known for its tremendous
regenerative power [10]. Newts, however, dedifferenti-
ate mature muscle cells during the regeneration process
[10]. Downregulation of p53 [11] and activation of ERK
[12] are critical to the dedifferentiation process.
Numerous in vitro studies have been conducted with
the newt A1 muscle cell line to study the dedifferenti-
ation process. Studies with newt A1 myotubes show that
serum stimulation results in cell cycle re-entry [13–15].
This early dedifferentiation event is not seen in mamma-
lian myotubes. However, some dedifferentiation studies
have been successful in the mammalian C2C12 muscle
cell line [16]. C2C12 myotubes undergo dedifferentiation
in culture in response to fusion with newt cells [17], or
treatment with extracts from newt forelimb regenerates
[18]. While the C2C12 cell line is ideal for studying the
reversal of differentiation, recent studies have found that
the cell line has a deletion in the INK4a/ARF locus [19].
The INK4a/ARF gene encodes p16, a cyclin-dependent
kinase inhibitor, and p19, alternate reading frame (ARF)
that controls p53 function [20]. Since established cell
lines can become altered with time, in order to further
characterize dedifferentiation in mammalian cells, pri-
mary muscle cell lines should be used. Studies that have
attempted to induce dedifferentiation in primary myo-
tubes have found that in normal cells, cell cycle re-entry
does not occur [21, 22]. In contrast to the studies by
Schneider et al. [23] that showed cell cycle re-entry in
myotubes derived from an immortalized Rb-deleted cell
line, two studies have shown that Rb removal alone can-
not cause differentiated myotubes to re-enter the cell
cycle in a primary cell line [22, 21]. Pajcini et al. [19],
however, found that inactivation of Rb and p19ARF in
primary myotubes resulted in cell cycle re-entry. In
addition, inactivation of Rb and p19ARF led to downregu-
lation of differentiation markers including muscle creat-
ine kinase (MCK), myosin heavy chain (MHC), and
MRF4 and upregulation of cyclin D1 and cyclin E. This
study indicated that p19ARF might be the factor that im-
pedes cell cycle re-entry in terminally differentiated
muscle cells.
A previous study has suggested that newt extract de-
rived from the early limb regenerate has the ability to in-
duce cell cycle re-entry and dedifferentiation in
mammalian myotubes [18]. This would suggest that
mammalian cells may be capable of undergoing dediffer-
entiation, and that a factor(s) present in the newt extract
provides the trigger to initiate the response. However,
the studies were conducted in C2C12 cells, and so the
question remains whether this is a global capability com-
mon to all mammalian muscle cells or a selective re-
sponse by the INF4a/ARF-deleted C2C12 cells. Thecurrent study compares the responses of C2C12 and pri-
mary myotubes to newt regeneration-derived extracts
and determines whether there is something specific to
newt extract that might inactivate mammalian cell cycle
checkpoints and allow dedifferentiation.
Methods
Animals
Adult Notophthalmus viridescens red spotted newts were
purchased from Charles D. Sullivan Co. Inc. (Nashville,
TN). Animals were housed at 22 °C in large aerated tubs
with running dechlorinated water and fed weekly on live
blackworms. All experimental procedures were per-
formed under anesthesia by immersion in buffered 0.1 %
tricaine methanesulphonate (MS222, Sigma). Experi-
mental protocols were approved by the University of
Ottawa Animal Care and Veterinary Service.
Preparation of newt extract
Under anesthesia, an initial bilateral amputation was done
above the wrist. Forelimbs were re-amputated at 5 days
after the initial amputation 1 mm proximal to the initial
amputation site and the regenerated tissues were collected.
The forelimbs were then re-amputated 3 days later, and
again after 1 day, as shown in Additional file 1. The sam-
pled tissues were immediately snap-frozen in liquid nitro-
gen and stored at −80 °C. The primary newt extract (1 °)
was prepared from first-time amputated tissues. Secondary
extract (2 °) was prepared from animals that were previ-
ously amputated, allowed to regenerate for 1 or 3 months,
and then re-amputated. As with the primary extract, tissues
were again collected at 5, 3, and 1 days after the amputa-
tion. Extract was made from the pooled tissue samples of
approximately 30 newts with slight variations to the proto-
col of McGann et al. [18]. Control extract was made from
the intact forelimb tissues. The frozen tissues were thawed
and placed in 10 ml High Glucose Dulbecco’s Modified
Eagle Medium (DMEM; Hyclone) supplemented with a
Protease Inhibitor Cocktail (Roche). One tablet of PIC was
dissolved in 1.5 ml of distilled water. One milliliter of the
dissolved solution was added to 9 ml of DMEM. The tis-
sues were homogenized for 5–10 min using a VDI 12 hand
homogenizer (VWR), and sonicated for 1–3 min with a
Misonix XL2000 sonicator. The homogenate was spun for
25 min at 2000 × g at 4 °C. The supernatant was then
placed in a fresh tube and spun for 60 min at 100,000 × g at
4 °C using an ultracentrifuge. The supernatant was filter
sterilized through a 0.4-μm filter. The extract concentration
was determined with a BCA protein assay kit (Bio-Rad)
and stored in 0.5 ml aliquots at −80 °C.
Fractionation of extract
One hundred microliters of crude extract at 2.5 mg/ml
was added to a Vivaspin 500 30 kDa molecular weight
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(Sartorius). The samples were spun for 30 min at
16,200 × g. The >30 kDa fraction that was retained on
the filter was resuspended in 25 μl. The concentration of
the separated fractions (≤30 kDa and ≥30 kDa) was ex-
amined with a BCA protein assay kit (Bio-Rad) and
stored at −80 °C. All procedures for preparation of ex-
tract were carried out at 4 °C.Differentiation of C2C12 cells
C2C12 cells were obtained from ATCC. Myoblasts were
grown to confluency on 100-mm plates (Corning Inc.) in
GM. To induce differentiation into multinucleated myo-
tubes, the cells were switched from GM with 10 % FBS
to differentiation medium (DM) containing 2 % horse
serum (Sigma).Isolation and differentiation of primary myoblasts
Primary myoblasts were isolated from the hindlimb
muscle of 4–6-week-old mice according to the protocol
of Springer et al. [24]. Myoblasts were grown in Ham’s
F-10 medium (Sigma), supplemented with 20 % FBS, 4X
pen/strep, 1X fungizone (Gibco), 50 μg/ml gentamicin
(Gibco) and 10 ng/ml basic fibroblast growth factor
(Sigma). Cells were grown on collagen-coated plates.
Once the primary myoblasts reached approximately
70 % confluency, they were switched to DM to induce
myotube formation.Effect of newt extract on myoblast proliferation
Flow cytometry analysis
Semi-confluent myoblasts that were grown in GM for
48 h with or without extract were trypsinized and
washed once in 10 % FBS-DMEM. Myoblasts were then
washed twice in PBS supplemented with 1 mM EDTA
(PBSE) and then fixed in 1 ml of PBSE by the drop-wise
addition of 2 ml of 80 % ethanol, pre-chilled to −20 °C.
The samples were stored at −20 °C for a minimum of
2 h, washed once in PBSE, resuspended in DNA content
staining buffer (1.1 % citrate buffer, 10 μg/μl propidium
iodide (Sigma), 0.1 mg/ml RNase) and incubated for
30 min at 37 °C before being analyzed on a Beckman-
Coulter flow cytometer using the Expo 32 software
package.Hemocytometer analysis
Myoblasts were plated on 100-mm plates (Corning Inc.)
in GM until they became semi-confluent. Cells were then
trypsinized and resuspended in GM. The same number of
cells (approx. 1.5 × 104) was plated either in the presence
or absence of newt extract. After 48 h in culture, the cells
were re-counted using a hemocytometer.Effects of newt extract on muscle differentiation
Myoblasts were kept in GM until they were 70 % conflu-
ent for primary cells and 100 % for C2C12 cells. The
myoblast cultures were then treated with 0.3 mg/ml of
newt blastema extract in DM or GM for 4 days followed
by immunostaining with MF20 antibody (1:50), which
stains myosin heavy chain (MHC). The control cells
were untreated, treated with heat-inactivated extract or
extract derived from intact forelimb tissue.
Purification of myotubes
AraC treatment
In order to remove contaminating myoblasts from the
myotube cultures, differentiated myotubes were trans-
ferred from DM to GM with 10 μM arabinosylcytosine
(AraC; Sigma) for 48 h. After treatment with AraC, the
cells were washed in phosphate buffered saline (1X PBS)
and transferred back into DM for a 24-h recovery period
prior to further treatments.
Cell filtration
In this alternative method for removing contaminating
myoblasts, day 4 differentiated myotubes were passed
through a 100-μM nylon mesh cell strainer (Fisher).
Large clumps of cellular debris were retained on the fil-
ter. The eluate was passed through a 40-μM mesh to get
rid of most of the contaminating myoblasts. Myotubes
that were retained on the filter were resuspended in
medium and re-plated onto culture dishes.
Tracking of differentiated cells
Proliferating C2C12 myoblasts cultured in 10 % FBS
were co-transfected with both 5-μg pCMV-EGFP/RFP
(Addgene) and 5-μg MCK-Cre (Addgene) plasmids using
Exgen500 reagent (Fermentas). Cells were maintained
under G418 selection. When the cells reached con-
fluency, the medium was switched to 2 % HS to induce
differentiation.
In a separate experiment, tracking of differentiated
myotubes was accomplished by microinjection of a GFP
plasmid (pEGFP-Cl, Addgene, 100 ng/μl) directly into
the myotubes. The plasmid was loaded into a FemtoTip
needle (Eppendorf ) using a microloader. For the injec-
tion, an injection pressure of 150 hPa, a maintenance
pressure of 50 hPa, and an injection time of 0.1 s was
used.
Treatment of myotube cultures with newt extract
Myotubes were treated with 0.1 mg/ml or 0.3 mg/ml of
primary (1 °) or secondary (2 °) newt extract in 2 % horse
serum or 10 % fetal bovine serum for 3–10 days. In the
presence of newt extract, 1 mM bromodeoxyuridine
(BrdU; Invitrogen) was added to the cells. Control cells
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Detection of apoptotic cells
Apoptotic cells were identified using terminal deoxynu-
cleotidyl transferase (TdT)-mediated dUTP nick end la-
beling (TUNEL) using the ApopTaq Fluorescein or
ApopTaq Red In situ Apoptosis Detection Kit (Chemicon)
according to the manufacturer’s instructions. C2C12 con-
trol and extract-treated cells were pre-fixed in 1 % PFA in
PBS (pH 7.4) for 10 min at RT. The cells were post-fixed
at −20 °C for 5 min in 2:1 ethanol:acetic acid. After the
washes, the fixed cells were incubated with the kit re-
agents, followed by MF20 antibody staining, after which
they were examined by fluorescence microscopy.
Microinjection of myotubes with newt extract
Preparation and injection of cells
Day 3 myotubes were purified using filtration (as de-
scribed above). Filtered C2C12 cells were plated on 35-
mm non-coated plates, or plates coated with 0.8 % so-
dium hyaluronate or 0.4 % collagen. Primary myotubes
were plated on either 0.8 % sodium hyaluronate or 0.4 %
collagen. Microinjection was performed using a micro-
manipulator and a Zeiss inverted microscope. Myotubes
were microinjected with 1:1 ratio of extract (at approx.
4 mg/ml) and 100 ng/μl of GFP plasmid (pEGFP-Cl,
Addgene). The extract/plasmid mixture was loaded into
a FemtoTip needle and the injection parameters were as
described above. From 25 to 60 myotubes were microin-
jected with the extract/plasmid cocktail. Right after the
injection, the cells were transferred to 10 % FBS for 3 or
4 days. Control myotubes were microinjected with
DMEM or MEF extract and GFP plasmid.
Immunocytochemistry
Control or extract-treated cultures were washed with 1X
PBS before fixation. Cells were fixed in 4 % paraformal-
dehyde (PFA) for 5 min at room temperature, followed
by 3 washes of 1X PBS for 5 min each. The primary
antibodies incubated with the cells included the follow-
ing: monoclonal antibody BrdU, 1:500 dilution (Molecu-
lar Probes); monoclonal antibody Ki-67, 1:200 dilution
(Sigma); monoclonal antibody p21, 1:50 (BD Biosciences,
Pharmingen); polyclonal antibody MF20, 1:50 (Santa
Cruz Biotechnology) and monoclonal antibody GFP,
1:200 (Invitrogen). The secondary antibodies were goat
anti-mouse Alexa Fluor 488 (Invitrogen) and anti-rabbit
Cy3 (Jackson Immuno Research, 1:400 dilutions for
both). Fluorescence was observed on a Zeiss Axiovert or
Nikon inverted microscope.
For the BrdU assay, several additional steps were per-
formed prior to the addition of the primary antibody.
Cells were blocked in 5 % goat serum (Jackson ImmunoResearch), 0.3 % Triton X-100 (Sigma) in PBS for
30 min at room temperature. The cells were then incu-
bated in 1 N HCl (Sigma) for 10 min on ice, followed by
2 N HCI for 10 min at room temperature and for
20 min at 37 °C, and washed in PBS (3X, 5 min each).
To buffer the cells, 0.1 M borate buffer (ACP Chemical
Inc) was added for 12 min at room temperature.
Fragmentation and proliferation assay
Fragmentation was assessed by following newt-extract-
treated myotube cultures with a Zeiss live imaging
microscope. C2C12 and primary cultures were differenti-
ated for 2 days followed by AraC treatment as described
above for 2 days. The cells were then placed back into
DM for 1 day followed by newt extract for 3 days at a
concentration of 0.3 mg/ml in DM. Cells were followed
with the Zeiss live imaging microscope and photo-
graphed every 15 min. Fragmentation and proliferation
were also assessed in both primary and C2C12 GFP
myotubes that were microinjected with a 1:1 ratio of
GFP plasmid (100 ng/μl) and newt extract.
Real-time polymerase chain reaction (RT-PCR) analysis for
myogenin
Total RNA was isolated from extract-injected and con-
trol myotubes at 96 h after injection of extract/GFP or
DMEM/GFP. RNA was isolated using the RNeasy mini-
kit (Qiagen). RNA concentration was determined on a
spectrophotometer and the quality of RNA was verified
by electrophoresis on a 1 % agarose gel. Equal amounts
of RNA were reverse transcribed with oligo dT-primers
to give complementary DNA (cDNA) using a cDNA
synthesis kit (Bio-Rad). RT-PCR was conducted using
the SYBR green system (Bio-Rad). Gene-specific primers
for myogenin were designed using Primer Software Ver-
sion 3. PCR was performed using primers 5′-GCAATG-
CACTGGAGTTCG-3′ and 5′-ACGATGGACGTAAGG
GAGTG-3′ on the Bio-RAD iCycler at 95 °C for 5 min
followed by 35 cycles of 95 °C for 30 s, 58 °C for 30 s,
72 °C for 30 s. Expression profiles were normalized
against GAPDH (primers 5′-TCGGTGTGAACG-
GATTTG-3′ and 5′-GGTCTCGCTCCTGGAAGA-3′).
Expression levels were calculated using the 2-ΔΔCT
method. The quality of the PCR products was examined
by electrophoresis on a 1 % agarose gel.
Statistics
The data are presented as means ± standard deviation.
The statistical calculations were done using GraphPad
Prism 5. Differences between control and treated sam-
ples were analyzed using a two-way ANOVA or a Stu-
dent t-test. P values less than 0.05 were considered
significant.
Fig. 1 Inhibition of muscle differentiation in C2C12 cells treated with
newt extract. a C2C12 myoblasts treated with 0.3 mg/ml of newt
extract in either differentiation medium (DM) or growth medium
(GM) showed impaired differentiation and reduced numbers of
MHC-positive cells. b The percentage of MHC-positive cells was cal-
culated by adding all MHC-positive cells (myotubes and myocytes)
and dividing by the total number of cells. The percentage of MHC-
positive cells was reduced in extract-treated cells in both DM and
GM. Scale bar = 200 μm. *p < 0.0001
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The effect of newt extract on myoblast proliferation
Newt extract was isolated (see Additional file 1) using
slight modifications of the published protocol [18]. Since
a single batch of extract was not sufficient to conduct all
the experiments described here, we tested various iso-
lates of extract. We also compared the efficacy of pri-
mary extract (isolated from newly amputated tissues)
and secondary extract (resulting from the re-amputation
of 1–3-month regenerated tissues). We reasoned that
perhaps regenerating tissues (used to generate the sec-
ondary extract) might be “primed” by the regeneration
process and might produce a more effective and more
“potent” extract.
Before testing the effects of the extract on fully differ-
entiated muscle cells, we assessed the effects on prolifer-
ation of myoblasts. Cell proliferation was analyzed using
flow cytometry in C2C12 semi-confluent cells treated
with newt extract. Equal numbers of cells were plated in
both control and extract-treated cultures. After 48 h, the
cells were harvested for flow cytometry analysis (Add-
itional file 2A, B). There were no apparent effects on cell
cycle in myoblasts that were treated with 1° newt extract
at 0.3 mg/ml in comparison to the control. Cell prolifer-
ation was also analyzed using a hemocytometer. Semi-
confluent myoblasts were plated with the same number
of cells in 1 ml of growth medium (GM) either in the
presence or absence of newt extract. After 48 h in cul-
ture, the cells were re-counted using a hemocytometer.
Again, there was no difference seen between the control
and the extract-treated cultures (Additional file 2C).
This indicates that the newt extract does not increase
proliferation in myoblast cultures.
The effect of newt extract on myoblast differentiation
Myogenic differentiation is typically studied in vitro by
the fusion of myoblasts into multinucleated myotubes.
To examine the effect of newt extract on myoblast dif-
ferentiation, the newt extract at a concentration 0.3 mg/
ml was added to subconfluent C2C12 myoblasts, and
when these cultures reached confluence, they were
transferred to differentiation medium (DM) or GM for
4 days; then the cells were analyzed for their ability to
undergo myogenic differentiation. When confluent myo-
blasts were cultured without newt extract in both DM
and GM for 4 days, the cells underwent differentiation
to form multinucleated myotubes (Fig. 1a). Cells grown
in differentiation medium formed larger and more nu-
merous myotubes, as might be expected, but even in
growth medium, confluent myoblasts exited the cell
cycle and formed myosin heavy chain (MHC)-positive
myotubes. In contrast, the newt extract-treated cells
formed fewer multinucleated myotubes than the control
(Fig. 1a) and they were much smaller in size. Asignificant decrease in the expression of myosin heavy
chain (MHC) was observed in the extract-treated culture
compared to the control in GM and DM (Fig. 1b). This
suggests that newt extract has effects on myoblast differ-
entiation and on myoblast fusion into multinucleated
C2C12 myotubes.
The effect of newt extract on primary myoblast differ-
entiation was also assessed. Primary myoblasts were
grown to 70 % confluency in GM, and were then
switched to DM in the presence or absence of newt ex-
tract. Within 24 h, myotube formation was observed in
the control cultures (Fig. 2a). Myotubes increased in
number and in size with time. In the extract-treated cul-
tures, however, there was a significant decrease in the
number of myotubes (Fig. 2a). This was manifested as a
reduction in MHC-positive cells in comparison to the
control cells (Fig. 2b), but this effect was not as pro-
nounced as with the C2C12 cells. Myoblast fusion, on
the other hand, was severely affected (Fig. 2c). This sug-
gests that, unlike C2C12 cells in which both myoblast
differentiation and fusion are severely affected by
Fig. 2 Inhibition of differentiation in primary myoblasts treated with newt extract. a Primary myoblasts treated with 0.3 mg/ml of newt extract for 72 h
showed reduced numbers of myotubes. b The percentage of myosin heavy chain (MHC)-positive cells (see Fig. 3b for method of calculation) was reduced
in extract-treated cells. c Fusion index was reduced in primary myoblasts treated with 0.1 mg/ml or 0.3 mg/ml of extract. The degree of reduction was
related to the concentration of the extract. Fusion index was calculated as the number of nuclei within multinucleated myosin-positive cells divided by the
total number of nuclei × 100. Scale bar= 200 μm. *p< 0.05
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pronounced effects on myoblast fusion, and less on dif-
ferentiation. The effects appear to be concentration-
dependent, since 0.1 mg/ml of extract had a smaller
effect than 0.3 mg/ml (Figs. 2b, c). Importantly, the pres-
ence of newt extract in the culture did not appear to
affect the proliferation of subconfluent myoblasts (either
positively or negatively), nor did it impact cell survival
(or apoptosis).
Cell cycle re-entry in AraC- and extract-treated C2C12
myotubes
McGann et al. [18] showed that mammalian C2C12
myotubes treated with newt extract could re-enter the
cell cycle and fragment into mononucleated cells. Our
first aim was to replicate the results in C2C12 myotubes
and then to extend them into the study of primary cells.
C2C12 myoblasts were grown to confluency and induced
to differentiate into multinucleated myotubes. In order
to remove contaminating myoblasts from the culturesand obtain purer myotube populations, cultures were
treated with AraC, a cytosine analog that incorporates
into replicating DNA, prevents the cell from dividing,
and leads to cell death. Subsequently, the differentiated
cells were treated with newt extract for 3 days in the
presence of BrdU in either GM or DM. We included
GM in the extract treatments because we reasoned that
if the cells were induced to re-enter the cell cycle, they
would need supporting nutrients to prevent them from
undergoing apoptosis. Control cells were treated with
heat-inactivated extract or extract derived from intact
newt forelimb tissues. Cells were then fixed and stained
with anti-BrdU antibodies to assess cell cycle re-entry,
and MF20 to label MHC-positive myotubes.
Differentiated C2C12 cells are capable of re-entering
the cell cycle following treatment with newt extract at a
concentration of 0.3 mg/ml (Fig. 3a). Interestingly, cell
cycle re-entry was almost exclusively seen in myocytes
(mononucleated MHC-positive cells) or very small myo-
tubes (two nuclei). Cell cycle re-entry in MHC-positive
Fig. 3 Cell cycle re-entry in C2C12 myotube cultures. Myotube cultures were treated with AraC to eliminate cycling myoblasts, and then treated
with various concentrations of 1° or 2° newt extract in the culture medium. a Arrow in treated culture identifies MHC-positive myotube that was
also positive for BrdU. Scale bar = 100 μm. b Following extract treatment in GM, the percentage of MHC-positive cells was determined (number of
myotubes divided by total number of cells for left panel and number of myocytes divided by total number of cells for middle panel). Extract treat-
ment led to significant reductions in myotubes and small increases in myocytes. In cultures treated with 0.3 mg/ml of secondary (2 °) extract,
23 % of MHC-positive myocytes incorporated BrdU. c Similar to (b), extract treatment in DM not only led to a reduction in myotubes but also led
to a significantly increased number of MHC-positive mononucleated myocytes. *p < 0.0001
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there was a significant decrease in multinucleated myo-
tubes in cultures treated with newt extract in both GM
(Fig. 3b) and DM (Fig. 3c), and this was accompanied by
a significant increase in mononucleated myocytes when
cells were treated in differentiation medium (Fig. 3c),
suggesting that some of the decrease in myotube num-
bers may have resulted from fragmentation of multinu-
cleated myotubes into mononucleated myocytes. The
effect was dependent on the concentration of extract
used, and the source of the extract. Not all batches of
extract were equally effective. In fact, cell cycle re-entry
was only induced in approximately 1/3 of the extracts
we isolated. Coomassie blue staining of Western blots
comparing four isolates revealed slight differences in the
presence and concentrations of the proteins present inthe different extracts (see Additional file 3). Interestingly,
the most potent effects on fragmentation and cell cycle
re-entry were obtained with 2 ° extract (obtained from
newts that had undergone regeneration and were then
re-amputated). In the experiment above, following treat-
ment with 2 ° extract in GM, 23 % of MHC-positive
myocytes were also positive for BrdU (Fig. 3b).
No cell cycle re-entry in AraC- and extract-treated primary
myotubes
Primary myoblasts underwent the same protocol of dif-
ferentiation, AraC and extract treatment as C2C12 cells.
Cell cycle re-entry was assessed by BrdU incorporation.
In primary muscle cells, cell cycle re-entry was almost
never observed in MHC-positive multinucleated or
mononucleated cells treated with newt extract. In
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showed BrdU incorporation in one of its multiple nuclei
(Additional file 4). In this case, it is probable that a div-
iding myoblast incorporated BrdU before fusing with an
existing myotube. In addition, a significant decrease in
MHC-positive myotubes was observed in cultures
treated with newt extract. This was not accompanied by
an increase in MHC-positive mononucleated cells, which
might indicate that the decrease in myotubes resulted
from cells dying and lifting off the plates.
Combined AraC and extract treatment induces apoptosis
in myotubes
Since the loss of myotubes seen in Fig. 3b, c could not
solely be accounted for by fragmentation into myocytes,
it is also possible that newt extract can induce apoptosis
of myotubes. In fact, we noted a significant loss of large
myotubes in extract-treated cultures. We conducted ter-
minal dUTP nick end labeling (TUNEL) analysis in
order to detect apoptotic cells. AraC-treated myotubes
that were also treated with newt extract in GM showed
a significant increase in TUNEL positive nuclei in com-
parison to the controls (Additional file 5A). This effect
was dependent on the concentration of extract used and
on the source of extract (with some batches showing in-
creased toxicity, data not shown).
To further assess if the effect was being caused by
newt extract or AraC (or both), we conducted a com-
parison between AraC- and non-AraC-treated myotubes
that were also treated with newt extract. In the presence
of newt extract, there appeared to be fewer and smaller
myotubes, but only in the AraC-treated cultures
(Additional file 5B). In other words, it appears that AraC
treatment in combination with extract treatment in-
duced the death of larger myotubes but appeared to
spare many of the smaller myotubes with reduced num-
bers of nuclei. Possible reasons for this are discussed
below.
Genetically labeled myocytes incorporate BrdU following
extract treatment
The above experiments showed cell cycle re-entry in
C2C12 multinucleated myotubes treated with newt ex-
tract. In order to eliminate the possible explanation that
BrdU-incorporating myoblasts were fusing with existing
myotubes to give these results, or were exiting the cell
cycle after incorporating BrdU, we used a two-plasmid
labeling system to identify differentiated cells. To label
cells, proliferating C2C12 myoblasts were co-transfected
with two plasmids, pCMV-EGFP/RFP, and MCK-Cre
[25]. The first plasmid encodes a loxP-flanked green
fluorescent protein (GFP) gene driven by the cyto-
megalovirus (CMV) promoter, and a red fluorescent pro-
tein (RFP). With this system, myoblasts express GFP.During differentiation, MCK-Cre is activated leading to
excision of the loxP-flanked GFP gene, resulting in ex-
pression of RFP in differentiated myocytes or multinu-
cleated myotubes (Fig. 4a).
Following differentiation, the RFP-expressing cultures
were treated with newt extract in DM. BrdU was added
to the cells at 72 h (after they had exited the cell cycle
and already expressed RFP). At 96 h, the cells were fixed
and stained for BrdU. Time-lapse images showed RFP-
expressing myocytes which subsequently incorporated
BrdU (Fig. 4b). This experiment was performed in tripli-
cate, and multiple wells were studied for each replicate;
BrdU incorporation in RFP-expressing cells was only
seen in the extract-treated cultures.
Differentiation-specific muscle markers are
downregulated following extract treatment
Dedifferentiation should not only involve cell cycle re-
entry but should also involve the downregulation of
muscle-specific markers such as myosin heavy chain
(MHC). In order to study downregulation of MHC,
C2C12 myoblasts were differentiated and the resulting
cultures were filtered to remove contaminating myo-
blasts. Filtering involved the passage of myotubes
through 100- and 40-μm mesh, which allowed the undif-
ferentiated myoblasts to pass through but retained the
myotubes on the filters. This method was used rather
than AraC treatment to avoid the substantial apoptosis
of myotubes seen above. The filtered myotubes were re-
plated, and following 24 h of recovery, multinucleated
myotubes were microinjected with a GFP plasmid to
allow tracking of myotubes. Cultures were treated with
newt extract in DM at a concentration of 0.3 mg/ml of
medium. Cells were treated for 6 days in DM and then
switched to GM for a further 4 days. The cells were then
fixed and stained with GFP and MHC antibodies.
We identified extract-treated C2C12 cells that were
positive for GFP but negative for MHC (Fig. 5a). Since
only multinucleated myotubes were injected with the
GFP plasmid, the GFP+ cells that were negative for
MHC could only have resulted from downregulation of
the MHC marker. Since not all myotubes in the cultures
were injected with the plasmid, counts were conducted
to determine the proportion of cells that were expressing
GFP or MHC. Notably, MHC−/GFP+ cells were only
seen in extract-treated cultures (Fig. 5b). Control (non-
extract-treated) GFP-injected cells were always positive
for both MHC and GFP (Fig. 5a, b). Interestingly, not
only did we identify myotubes that had downregulated
the MHC marker, but we also found mononucleated
myocytes that expressed GFP but not MHC. Since only
multinucleated myotubes were injected with the GFP
plasmid, this would suggest that fragmentation was also
occurring in addition to downregulation of MHC.
Fig. 4 Further evidence of cell cycle re-entry in C2C12 myotube cultures. a Schematic diagram of plasmid vectors used to label cells. With these
vectors, myoblasts express GFP. Upon differentiation, cells express MCK, leading to the expression of Cre and the excision of the GFP gene.
Differentiated myotubes and myocytes are thus labeled with RFP. b BrdU was added to the cultures at 72 h and cells were fixed at 96 h and
stained for BrdU incorporation (green). Arrow and arrowhead identify the same myocytes in all four panels at 96 h, showing nuclear BrdU
expression in the RFP-expressing cells. At the same time, the bottom panels also show cytoplasmic diffuse GFP expression in
neighboring myoblasts
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During muscle differentiation, the expression of p21 in-
creases followed by cell cycle withdrawal in myocytes.
These myocytes eventually express mature muscle
markers such as MHC, and then start fusing, forming
multinucleated myotubes [26].
C2C12 myoblasts were allowed to differentiate for
5 days. Newt extract in growth medium (GM) was added
to the differentiated cells for 3 days followed byimmunostaining for p21. A significant decrease in p21
expression was seen in mononucleated cells in treated
cultures (Fig. 6 and Table 1, p = 0.015). There was also a
significant increase (p = 0.048) in the p21-/MHC- mono-
nucleated cells (Fig. 6 and Table 1). This suggests that
newt extract may block differentiation by blocking p21
expression or may have the ability to downregulate p21
expression in myocytes and thus prevent differentiation
and MHC expression.
Fig. 5 Evidence of downregulation of muscle-specific markers following treatment with newt extract. C2C12 myotubes were microinjected with a GFP
tracer and subsequently treated with newt extract for 4 days in growth medium. They were then fixed and stained for myosin heavy chain (MHC).
a The arrow identifies GFP-labeled cells that were not positive for MHC, suggesting that they had downregulated the MHC marker. Not all myotubes
responded to the extract, as can be seen by GFP-labeled cells that were also positive for MHC. b Cell counts of multinucleated myotubes (left panel)
and mononucleated myocytes (within the same cultures) showed that only extract-treated cultures had GFP-positive cells that were negative for MHC.
This experiment was performed in triplicate, and multiple wells were counted for each replicate
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myotubes
Microinjection of extract into multinucleated myotubes
(rather than adding extract to the medium) was used as
an alternative method of treatment that guaranteed that
only differentiated cells were targeted. Myotubes wereFig. 6 p21 expression is downregulated by treatment with newt extract (se
they exit the cell cycle, and in MHC-expressing myocytes. In extract-treated
to be lost. However, larger myotubes retain p21 expressioninjected with a combination of extract and GFP plasmid
to allow tracking of the injected cells.
In preparation for microinjection, C2C12 cells were
differentiated for 3 days and then filtered. The resulting
myotubes were plated on 35-mm plates in DM. Multinu-
cleated cells (of greater than 3 myonuclei) weree also Table 1). In control cells, p21 expression is seen in myoblasts, as
cultures, the extensive p21 expression in mononucleated cells appears
Table 1 A decrease in p21 expression in mononucleated cells
following treatment with newt extract
p21+/MHC+ p21+/MHC− p21−/MHC−
Control 2.69a 11.34 76.4
0.3 mg/ml 2.05 3.42 81.4
p value 0.306 0.015 0.048
All nuclei were counted (both in multi-nucleated myotubes and mono-
nucleated myocytes and myoblasts), but only mono-nucleated cells are
shown here
aPercentage of total nuclei
Fig. 7 Injection of newt extract directly into C2C12 myotubes. Myotubes w
a Arrows identify GFP-positive cells that were also positive for Ki67 (a prolif
injected myotubes were positive for Ki67. There were also GFP/Ki67-positiv
presence of GFP-positive myocytes suggests that fragmentation may have
downregulation of myogenin in extract-treated cultures. *p < 0.05, **p < 0.0
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mid (Fig. 7). The control cells were microinjected with
the GFP plasmid and Dulbecco’s Modified Eagle
Medium (DMEM), which was the vehicle in which the
extract was dissolved. As an additional control, we also
tested extract isolated from mouse embryonic fibroblasts
(MEFs), a rapidly dividing cell line. After microinjection,
the cells were transferred to growth medium containing
10 % fetal bovine serum (FBS) for 3 or 4 days. This was
followed by staining with Ki-67 (a proliferation marker)
and GFP.
In our preliminary studies on microinjection, we com-
pared the results obtained with injection of complete ex-
tract with those of fractionated extract (the extract was
separated into two fractions: >30 kDa and <30 kDa).ere microinjected with either DMEM/GFP (control) or Extract/GFP.
eration marker). b Cell counts showed that greater than 40 % of the
e myocytes. Since only multinucleated cells were microinjected, the
occurred. c RT-PCR of microinjected cultures showed a significant
001
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fraction, and an incomplete response from all nuclei within
a myotube for the complete extract. The >30 kDa fraction
gave the best results, and so all subsequent microinjection
studies were conducted with this fraction.
C2C12 multinucleated myotubes that were injected
with both the newt extract and GFP re-entered the cell
cycle (Fig. 7). Approximately 45 % of the nuclei in GFP-
labeled multinucleated cells exhibited cell cycle re-entry
as shown by Ki-67 staining (Fig. 7b). Importantly, this
level of cell cycle re-entry was higher than that obtained
by incubating the cells with the extract, suggesting that
there may be proteins in the extract that impact cell
cycle re-entry but are not able to cross the cell mem-
brane. Cell cycle re-entry was not observed in multinu-
cleated cells injected with DMEM and GFP (Fig. 7b) or
cells injected with the fractionated MEF extract (data
not shown). In addition, mononucleated myocytes which
were GFP and Ki-67 positive were only found in cultures
injected with the newt extract and GFP (Fig. 7b). Since
the microinjection was done in multinucleated cells, the
presence of GFP-positive myocytes would suggest that
the myotubes were fragmenting. We also examined the
levels of expression of myogenin, another differentiation-
specific muscle marker. RT-PCR analysis showed a signifi-
cant downregulation of myogenin in extract-injected cul-
tures (Fig. 7c). Importantly, there was no evidence of
apoptosis in any of our cultures, suggesting that the
microinjection itself is not toxic to the cells.
There is no cell cycle re-entry in extract-microinjected pri-
mary myotubes
Similar to the C2C12 studies, primary myotubes of three
nuclei or more were microinjected with newt extract
and GFP. Newt extract did not induce cell cycle re-entry
in primary myotubes (data not shown). Cell cycle re-
entry was also not observed in the control cells which
were injected with DMEM and GFP. Since a number of
studies have suggested that the extracellular matrix is
critical for dedifferentiation and regeneration in the
newt, we assessed whether coating of the plates with col-
lagen or sodium hyaluronate would influence cell cycle
re-entry. Neither substrate was able to support cell cycle
re-entry in primary myotubes (data not shown).
Fragmentation of extract-treated C2C12 myotubes
The above studies suggest that fragmentation of C2C12
multinucleated myotubes is occurring to yield mononu-
cleated myocytes. To confirm this, C2C12 differentiated
myotubes were treated with newt extract at 0.3 mg/ml,
and followed with Zeiss live imaging microscopy. As
shown in Fig. 8, the initial sign of C2C12 myotube frag-
mentation into two small myotubes was observed after
63 h. After a further 9 h in culture, the fragmented cellswere still present in the culture, suggesting that they
were still viable.
Fragmentation of extract-microinjected C2C12 myotubes
To assess whether myotubes microinjected with newt
extract can undergo fragmentation and proliferation,
C2C12 cells were differentiated for 3 days and then fil-
tered. The filtered cells were re-plated on 35-mm plates
coated with 0.4 % collagen. The collagen coating of the
plates reduced the degree of cellular migration and
allowed better tracking of cells. The following day, the
cells were injected with newt extract and GFP plasmid.
Control cells were injected with DMEM/GFP. The ex-
pression of GFP in myotubes was not detected until at
least 24 h after the injection. For that reason, the cells
were followed by Zeiss live imaging microscopy starting
at 48 h, and images were taken every 15 min. The initial
sign of C2C12 myotube fragmentation was observed at
approx. 82 h, and the fragmented cells were noticeable
as two distinct cells after 90 h (Additional files 6 and 7).
Fragmentation of extract-microinjected primary
myotubes
Even though cell cycle re-entry was not seen in primary
myotubes treated with the newt extract, we observed
that cultures treated with newt extract and GFP had a
significant decrease in multinucleated cells and increase
in myocytes (one or two nuclei positive for MHC) in
comparison to the control (Fig. 9). The decrease in mul-
tinucleated cells and the increase in myocytes might in-
directly indicate that the newt extract caused
fragmentation of multinucleated cells into myocytes. In
order to examine this, we tracked injected primary myo-
tubes with the live imaging microscope. In primary cells,
the initial sign of fragmentation was seen after 112 h
and 35 min (Additional files 8 and 9). By 121 h and
26 min, the cells were fully separated from one another.
The cells continued to survive in culture until the ex-
periment was stopped at 263 h and 26 min (data not
shown). Myotubes injected with DMEM/GFP did not
undergo fragmentation.
Discussion
Overall, our results show that newt-derived extracts can
block the differentiation of both primary and C2C12
myoblasts. Based on our experiments with differentiated
C2C12 cultures, we believe that one of the mechanisms
by which extract can prevent differentiation of myoblasts
may be by preventing the upregulation of p21, which
has been shown to cause cell cycle exit during differenti-
ation [26]. A similar inhibition of differentiation was
seen by Kim et al. [27] using extract isolated from the
blastema of the teleost, Sternopygus macrurus. However,
the teleost extract was also able to induce proliferation
Fig. 8 C2C12 myotube (arrow) treated with newt extract at a concentration of 0.3 mg/ml (1°) in GM is undergoing fragmentation. The resulting
cells remained viable and did not lift off the plate
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effect by our newt extracts. However, it is noteworthy
that Kim et al. treated their cells in differentiation
medium (DM), whereas we treated our cells in growth
medium (GM). It may be that our cells were already
proliferating maximally. We suspect that if we treated
our cells in DM, there would probably have been a pro-
liferative effect, similar to the electric fish, since it is in-
evitable that the newt extracts have growth factors
which are required for the proliferation of the dediffer-
entiated blastema cells. We did not only conduct our
proliferation assays in GM but also conducted many of
our extract treatments in GM as well. We reasoned that
if cells entered the cell cycle, they would need growth
factors available to them so that they could proceed
through the cell cycle rather than undergoing apoptosis.
Importantly, similar to the results of McGann et al.
[18], we found that newt extracts are able to induce cell
cycle re-entry and fragmentation of C2C12 myotubes,
something which did not occur with the teleost extract.
However, the extracts are not able to induce cell cycle
re-entry and are only able to induce fragmentation in
primary myotubes. In order to ensure that the results we
obtained were robust, we used several different methods,including incubation, microinjection, and cell tracking to
show that newt extract can induce cell cycle re-entry.
All these methods were successful in C12C12 cells but
none showed cell cycle re-entry in primary cells. This
suggests that C2C12 cells have acquired mutations in
culture that may allow them to re-enter the cell cycle. In
fact, studies comparing C2C12 cells to primary myo-
blasts have shown that C2C12 cells have tumorigenic
potential [28], have mutations in p19ARF [19], respond
differently to p53 [29], and show changes in adhesion
protein expression [30]. All of these changes may con-
tribute to their ability to respond to newt extracts. Fur-
thermore, the fact that we only saw cell cycle re-entry in
smaller myotubes or myocytes suggests that these cells
may be “less differentiated” than the large myotubes and
more capable of fragmentation, and this is why they
preferentially respond to newt extract. Our studies with
p21 would also seem to support this suggestion, as we
found no differences in p21 expression in multinucleated
myotubes following treatment with newt extract but saw
significant downregulation in mononucleated myocytes
and myoblasts.
In primary cells, it is possible that we did not identify
the ideal conditions to induce cell cycle re-entry.
Fig. 9 Treatment with newt extract induced fragmentation of primary
myotubes. Primary myotubes did not re-enter the cell cycle but were
induced to fragment following treatment with 0.3 mg/ml of extract.
a Visible changes to myotube morphology and structure were seen by
treatment with extract. b Cell counts showed a significant drop in the
number of myotubes and a significant increase in the number of
myocytes following treatment with extract. This suggests that
fragmentation is occurring
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is critical during the dedifferentiation process since it
controls tissue stiffness and influences DNA synthesis,
cell migration, myotube fragmentation, and myoblast fu-
sion [31, 32]. In our studies, we coated the primary myo-
tube plates with collagen and hyaluronic acid and found
no evidence of cell cycle re-entry, although we were able
to induce fragmentation. It thus remains a possibility
that we simply did not identify the optimal conditions to
induce cell cycle re-entry.
Interestingly, we found that not all sources of extract
were equally effective. With some sources of extract, the
number of cells undergoing cell cycle re-entry were ex-
tremely limited (only a few cells in the culture), while
other sources of extract showed 25–30 % cell cycle re-
entry (and even greater when the extract was microin-
jected into myotubes rather than added to the culture
medium). Coomassie stained Western blots of different
batches of extract revealed slight differences in the con-
centrations (or even presence) of certain proteins. The
reasons for this variability are not entirely clear. It may be
related to the health of the animals or the variability in the
rate of regeneration. In some cases, the animals were
clearly smaller and less hearty, and potentially battling
other health issues (such as parasitic infections). This was
very difficult to control since the newts were wild-caught,
and some seasons are better than others in terms of theirhealth and their growth. Overall, only approximately 1/3
of the extracts tested showed cell cycle re-entry. Unfortu-
nately, it was too difficult to conduct all experiments with
the same batch of extract since the yield of extract was
not large. This disadvantage also served as an advantage
because we can conclusively say that the results obtained
in this study were not just obtained with one source of ex-
tract but with multiple isolates.
In general, we found that secondary extract (i.e.,
extract obtained from newts undergoing a second round
of amputations within 1–3 months of the initial amputa-
tions) worked a little better than primary extract. Our
best results (highest levels of cell cycle re-entry and low-
est levels of toxicity and cell death) were obtained with
secondary extract.
One might argue that the reason why newt extracts in-
duced cell cycle re-entry in C2C12 cells was related to
the fact that they were isolated from rapidly dividing
cells in the early regenerate. This is unlikely since the
proliferation of blastema cells is not usually maximal in
the early regenerate (within 5 days of amputation).
Nevertheless, in order to eliminate the possibility that
cell cycle re-entry was induced by proliferation-inducing
proteins in the extract, we isolated extract from mouse
embryonic fibroblasts during their exponential growth.
These extracts had no effects on cell cycle re-entry, sug-
gesting that the cell cycle-inducing property is newt cell-
specific.
It is interesting to note that treatment with the cyto-
sine analog AraC induced death in myotubes (especially
larger myotubes with greater numbers of nuclei). While
we saw some evidence of this even in our control cul-
tures, it was much more pronounced in the cultures
treated with a combination of AraC and newt extracts.
We believe that the explanation for this may be the fol-
lowing: Cultures were treated with AraC to allow in-
corporation of the nucleotide analog into the DNA of
cycling myoblasts. This would normally lead to impaired
DNA replication and death of the myoblasts, yielding a
purer myotube population. We believe the AraC was
also taken up by myotubes. Even if the cultures were
then washed to remove excess AraC prior to extract
treatment, any AraC that was retained in the cells could
become incorporated into DNA if the cells were subse-
quently induced to undergo cell cycle re-entry by the ex-
tract treatment. Once this occurred, this would lead to
the death of the myotubes. For this reason, we switched
from AraC treatment to filtration in later experiments to
eliminate contaminating myoblasts from the myotube
cultures.
Conclusions
Overall, we have shown that newt extracts can induce
cell cycle re-entry of C2C12 myotubes, but they only
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esting to note that C2C12 cells have been previously
shown to re-enter the cell cycle following knockdown of
Rb, but that in primary cells, both Rb and p19ARF
knockdown are required to induce cell cycle re-entry
[19]. This suggests that C2C12 cells are in an interme-
diate state between newt A1 muscle cells (which can
re-enter the cell cycle following serum stimulation) and
primary cells, which require two mutation events for cell
cycle re-entry to occur.Additional files
Additional file 1: Procedure for isolation of newt extract. The primary
(1 °) newt extract was collected by first amputating above the wrist of
the newt forelimb to remove the intact tissue. After 5 days, the growing
regenerating pre-blastema was removed and frozen in liquid nitrogen.
After 3 days the limb was re-amputated, and then re-amputated again
the following day. The 1, 3 and 5-day regenerates were pooled. The
secondary (2°) extract was prepared from animals that had been previously
amputated, and allowed to regenerate for 1–3 months. Pooled tissues were
subjected to homogenization and centrifugation as described in the
“Methods” section.
Additional file 2: Extract treatment of subconfluent myoblasts did
not affect proliferation. A) Flow cytometry profiles for control C2C12
cells, or C2C12 cells treated with 0.3 mg/ml of newt extract showed no
visible differences between the two groups. B) Values obtained from flow
analysis showing the percentage of cells in each of the cell cycle
compartments appeared similar between control and extract-treated
cells. C) Cell counts analyzed with a hemocytometer agreed with flow
cytometry results. Values are shown +/− Standard Deviation.
Additional file 3: Coomassie blue-stained western blot of four
different extract isolates. Coomassie blue-stained western blot of four
different extract isolates (2 primary and 2 secondary extracts) shows that
the protein pattern is not identical between different batches of extract.
This may be the reason why some batches were more effective than
others in inducing cell cycle re-entry.
Additional file 4: Cell cycle re-entry was not seen in primary myotube
cultures. Myotube cultures were treated with AraC to eliminate cycling
myoblasts, and then treated with various concentrations of 1 ° or 2 ° newt
extract in the culture medium. Cultures were stained with MHC (green),
BrdU (red) and DAPI (nuclear stain). A) Control cultures showed no BrdU
incorporation in MHC-expressing cells. B) Extract-treated myotubes also
typically showed no BrdU incorporation. The BrdU positive nucleus (arrow)
in the myotube was the only one seen in all cultures treated, and probably
resulted from a cycling myoblast fusing with a pre-existing myotube.
Additional file 5: The effects of AraC treatment on myotubes.
A) TUNEL assay identified apoptotic cells in AraC treated C2C12
differentiated cells. The higher the concentration of extract, the more
toxicity was seen in myotubes. Cell death was only seen in extract
treatment combined with AraC. B) Comparison of AraC treated and
non-AraC-treated myotube cultures showed fewer and smaller myotubes
in the AraC and extract-treated cultures, suggesting that the combination
of AraC and extract caused death of larger myotubes. Each experiment
was performed in triplicate. *p < 0.0001 between the control and cultures
treated with 0.3 mg/ml.
Additional file 6: Fragmentation in C2C12 myotubes treated with
newt extract. C2C12 myotube (with what appeared like 3–4 nuclei),
injected with newt extract can undergo fragmentation. The arrows are
pointing to the same myotube as it is breaking down into two cells.
The images were taken every 20 mins using a Zeiss live imaging
microscope. The time shown is when the image was taken. D) inset,
shows an enhanced image of the cell (with 3–4 nuclei) prior to its
fragmentation (see accompanying time-lapse video (Additional file 7)).Additional file 7: Time lapse video of fragmenting C2C12 myotube.
Time lapse video of the images portrayed in Additional file 6 showing
fragmentation of a multinucleated C2C12 myotube.
Additional file 8: Treatment with newt extract induced
fragmentation of a primary myotube. Myotube cultures were tracked
with live imaging (see also time-lapse video (Additional file 9). The
arrowheads point to a GFP- and extract-injected myotube as it
undergoes fragmentation. The black arrowheads point to two cells
originating from a single myotube as they pull apart. The white
arrowhead identifies a third cell which also appears to originate from
the myotube, but may potentially be a cell which was above the plane
of the myotube in (B).
Additional file 9: Time-lapse video of fragmenting primary
myotube. Time-lapse video of the images portrayed in Additional file 8
showing fragmentation of a multinucleated primary myotubes.
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